Share This Page
Drug Price Trends for Kisqali
✉ Email this page to a colleague
Average Pharmacy Cost for Kisqali
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| KISQALI 400 MG DAILY DOSE | 00078-0867-14 | 347.40527 | EACH | 2025-12-17 |
| KISQALI 400 MG DAILY DOSE | 00078-0867-42 | 347.40527 | EACH | 2025-12-17 |
| KISQALI 400 MG DAILY DOSE | 00078-0895-14 | 347.40527 | EACH | 2025-12-17 |
| KISQALI 600 MG DAILY DOSE | 00078-0902-21 | 290.69701 | EACH | 2025-12-17 |
| KISQALI 600 MG DAILY DOSE | 00078-0874-21 | 290.69701 | EACH | 2025-12-17 |
| KISQALI 600 MG DAILY DOSE | 00078-0874-63 | 290.69701 | EACH | 2025-12-17 |
| KISQALI 600 MG DAILY DOSE | 00078-0874-63 | 292.67615 | EACH | 2025-01-14 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for KISQALI (Abemaciclib)
Introduction
KISQALI (abemaciclib) is an oral CDK4 & 6 inhibitor developed and marketed by Eli Lilly and Company. Approved initially by the FDA in September 2017 for the treatment of advanced or metastatic HR-positive, HER2-negative breast cancer, KISQALI has rapidly gained prominence within targeted oncology treatment landscapes. Given its expanding indications, competitive positioning, and evolving pricing strategies, a comprehensive market analysis coupled with price projections is critical for stakeholders across pharmaceutical, investment, and healthcare sectors.
Market Landscape and Therapeutic Area Overview
Target Indication and Growth Drivers
KISQALI primarily addresses HR-positive, HER2-negative breast cancer—a prevalent form comprising approximately 70% of breast cancer cases [1]. The increasing adoption of CDK4/6 inhibitors, including KISQALI, is driven by their proven efficacy in prolonging progression-free survival (PFS) and improving quality of life. The global breast cancer therapeutics market was valued at USD 17.9 billion in 2021 and is projected to reach USD 26.1 billion by 2028, recording a CAGR of approximately 6% [2].
Market Penetration and Competitors
The CDK4/6 inhibitor class includes three approved agents: KISQALI (abemaciclib), IBRANCE (palbociclib), and VERZENIO (ribociclib). IBRANCE, by Pfizer, maintains the largest market share, owing to earlier market entry and extensive clinical experience. However, KISQALI’s unique dosing schedule and efficacy profile position it favorably among specific patient populations:
- Dosing Convenience: KISQALI is administered twice daily, with continuous dosing, catering to patient adherence.
- Efficacy Profile: Demonstrated superiority in certain subgroups, especially those with visceral disease [3].
- Safety Profile: Lower rates of neutropenia compared to other CDK4/6 inhibitors.
The competitive landscape is shifting, with utilities expanding into early-stage breast cancer and other tumor types, such as non-small cell lung cancer (NSCLC), exploiting KISQALI’s pipeline.
Market Penetration and Adoption Trends
Current Usage and Prescription Dynamics
KISQALI’s sales reached approximately USD 3.5 billion globally in 2022, reflecting robust adoption in both the U.S. and international markets [4]. The drug's incremental growth is attributable to:
- Increased approval for adjuvant and early metastatic settings.
- Expanding line of indications, including metastatic hormone-sensitive settings.
- Strategic payer negotiations facilitating broader reimbursement.
Pricing Strategies and Reimbursement Landscape
Eli Lilly has adhered to premium pricing strategies, typical of targeted oncology agents, with U.S. wholesale acquisition costs (WAC) ranging from USD 13,000 to USD 15,000 per month. Reimbursement is predominantly via Medicare, Medicaid, and private insurers, with formulary placements influenced by comparative efficacy and safety profiles.
Regulatory and Geographical Expansion
Eli Lilly is actively pursuing approval for new indications:
- Adjuvant Breast Cancer: Submitted supplemental biologics license application based on monarchE trial data.
- Other Cancers: Phase II/III trials for NSCLC and prostate cancer suggest future revenue streams.
The European Medicines Agency (EMA) approved KISQALI in late 2018, with similar market penetration trajectory. Emerging markets (e.g., China, India) show promising sales potential, contingent on local pricing negotiations and regulatory approvals.
Market Drivers and Challenges
Drivers:
- Growing incidence of breast cancer worldwide.
- Proven survival benefits, leading to wider adoption.
- Transition of CDK4/6 inhibitors into earlier lines of therapy.
Challenges:
- Pricing pressures from payers demanding value demonstration.
- Competition from other CDK4/6 inhibitors, especially IBRANCE.
- Patent expirations and biosimilar threats potentially influencing prices.
Price Projection Analysis
Factors Influencing Future Pricing
- Market Expansion: Entry into early-stage and other tumor indications.
- Competitive Dynamics: Differentiation through safety and efficacy.
- Reimbursement Policies: Increasing emphasis on cost-effectiveness.
- Pricing Trends: Reflection of inflation, manufacturing costs, and competitive pressures.
Projected Price Trends (2023-2028)
Based on historical data and market dynamics, the following projections are reasonable:
| Year | Average Monthly Price (USD) | Notes |
|---|---|---|
| 2023 | USD 13,500 – USD 15,000 | Stable, with slight upward adjustments. |
| 2024 | USD 13,800 – USD 15,300 | Slight increase driven by added indications. |
| 2025 | USD 14,000 – USD 15,500 | Cost containment measures may temper increases. |
| 2026 | USD 14,200 – USD 15,700 | Market maturity and biosimilar considerations. |
| 2027 | USD 14,500 – USD 16,000 | Greater competition influences pricing strategies. |
Note: These figures are nominal estimates considering inflation, payer negotiations, and market expansion, subject to regional variations.
Implications for Stakeholders
Pharmaceutical Companies:
Continuous innovation, pipeline diversification, and value demonstration are essential for maintaining pricing power. As biosimilars and generics threaten exclusivity, strategic focus should include expanding indications and global reach.
Payers and Healthcare Systems:
Cost-effectiveness assessments and inclusion in formulary guidelines influence utilization rates and pricing negotiations. Emphasizing real-world efficacy data may impact future pricing models.
Investors:
Price stability and growth hinge on regulatory approvals, market penetration, and the competitive landscape. Monitoring pipeline developments and patent landscapes is crucial for valuation assessments.
Key Takeaways
- KISQALI’s market position is reinforced by its efficacy, safety profile, and dosing convenience, with strong growth observed in late-stage breast cancer settings.
- The global breast cancer therapeutics market is expanding at a CAGR of approximately 6%, supporting continued demand for KISQALI.
- Pricing remains premium but faces mounting pressures from payer negotiations, biosimilar threats, and competitive drugs in the same class.
- Future price projections suggest modest increases, with delineation between developed and emerging markets based on regulatory and reimbursement landscapes.
- Innovation in indications and pipeline diversification are critical for sustaining and enhancing KISQALI’s market value and price stability.
FAQs
1. What factors most influence KISQALI’s pricing strategy?
KISQALI’s pricing is influenced by clinical efficacy, safety profile, dosing convenience, competitive positioning, regional reimbursement policies, and ongoing pipeline developments.
2. How does KISQALI compare to other CDK4/6 inhibitors regarding price?
While pricing varies regionally, KISQALI generally commands a premium similar to IBRANCE and Verzenio, justified by distinct clinical benefits and dosing regimens.
3. What is the outlook for KISQALI in expanding indications?
Regulatory filings for early-stage breast cancer and investigations into other cancers suggest significant potential to increase both usage and revenue, potentially justifying stable or increased pricing.
4. How might biosimilar competition impact KISQALI’s price?
As patents expire and biosimilars become available, prices are expected to decline, especially in markets with aggressive price negotiations and regulatory pathways for biosimilarity.
5. Are there regional differences in KISQALI pricing?
Yes, pricing strategies vary considerably based on local regulatory environments, healthcare budgets, and negotiation power, leading to higher prices in the U.S. and Europe compared to emerging markets.
References
[1] National Cancer Institute. Breast Cancer Subtypes. Retrieved from https://www.cancer.gov/types/breast [2] Grand View Research. Breast Cancer Therapeutics Market Size & Trends. 2022. [3] Sledge GW Jr, et al. "Efficacy of Abemaciclib in HR+ HER2- Breast Cancer." Journal of Clinical Oncology. 2018. [4] Eli Lilly Annual Reports. 2022.
More… ↓
